IRISYS Chairman, CEO & Founder Gerald Yakatan, Ph.D., Participates in the 8th Annual Life Science CEO Forum

– Dr. Yakatan joins discussions with executives from pharmaceutical, biotechnology, medical device and diagnostic corporations –

San Diego, March 16, 2017 – IRISYS, LLC, a San Diego-based provider of contract pharmaceutical product development and manufacturing services, today announced that Gerald Yakatan, Ph.D., Chairman, CEO and founder of IRISYS, will be participating in The 8th Annual Life Science CEO Forum to be held in San Diego, California March 23-24, 2017.

The 8th Annual Q1 Life Science CEO Forum will gather executive leadership from pharmaceutical, biotechnology, medical device and diagnostic corporations to discuss not only the positive future of the industry, but also the challenges faced in continued regulatory demands, pricing and reimbursement challenges, as well as concerns surrounding market and political volatility.

“It is important for life sciences companies to stay current regarding issues such as the regulatory environment and the convergence of technology and healthcare,” said Gerald Yakatan, Ph.D., Chairman, CEO and founder of IRISYS. “Our IRISYS leadership team has built a reputation for excellence and expertise in pharmaceutical development services.  Participation in conferences such as the annual Life Science CEO Forum enables IRISYS to keep abreast of industry changes and provides a venue to share our knowledge and successes in a collaborative environment.”

The Forum includes a panel discussion that will address various factors impacting the life science industry today while forecasting future implications on manufacturers and external stakeholders.  Another session will focus on identifying market needs, matching products to those needs, and meeting scientific, regulatory and commercial milestones.

The intersection of IT and healthcare will be addressed in regard to developing novel therapies and medical devices in conjunction with powerful technologies. Attendees will get an inside look on how digital health continues to disrupt the life science industry, supporting innovation in product development and healthcare delivery.


IRISYS was founded in 1996 to provide contract pharmaceutical product development and manufacturing services, specializing in formulation development, cGMP manufacturing of clinical trial materials and commercial pharmaceutical products, and strategic consulting related to the drug development process. IRISYS’ custom approach to drug development is supported by the Company’s scientific and regulatory experience in moving more than 100 drug products from discovery to clinical development and commercialization.

About The Forum (

Participants will represent CEOs and Therapeutic Leadership from established organizations with commercial products and revenue, and a minimum number of employees to ensure a balanced level for education, engagement, and knowledge share focused on mutual challenges and opportunities. As with all Q1 programs, presenters will represent a variety of industry stakeholders, from serial entrepreneurs driving innovation to regulatory and market access authorities ensuring patients and physicians have access to the most appropriate therapies.

IRISYS Contacts

Louis Scotti
Vice President Business Development

Gwen Rosenberg
Rosenberg Business Communications
Please follow and like us:

Welcome to Societal™
Recro has a new name. And, with it, a renewed sense of what we can accomplish with our partners to expedite the delivery of life-changing pharmaceuticals to patients. Together, we are truly Bringing Science To Society. You will soon be able to explore our vision with the upcoming launch of our new website.